| 靶点: |
DNA topoisomerase I |
| 体内研究: |
In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies. |
| 参考文献: |
1. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. 2. Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004. |
| 保存条件: |
-80℃,充氩(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.449 ml |
12.243 ml |
24.486 ml |
| 5 mM |
0.49 ml |
2.449 ml |
4.897 ml |
| 10 mM |
0.245 ml |
1.224 ml |
2.449 ml |
| 50 mM |
0.049 ml |
0.245 ml |
0.49 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |